Drug Trial Radar · NCT06322342
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Last checked: Nov 20, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Aug 15, 2024
Primary completion
Dec 19, 2025
Study completion Dec 19, 2025
Sponsor
- Lead sponsor
- Reveal Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Mar 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Single (outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis. The goal of this study is to assess safety, efficacy, and pharmacokinetics of RVP-001 at three dose levels. The study will also compare RVP-001 imaging to gadolinium-based contrast agent (GBCA) imaging. A single dose of RVP-001 will be administered to each subject. Subjects will have known gadolinium-enhancing CNS lesions and will have a gadolinium-based contrast agent-enhanced MRI of the brain 2-14 days before receiving RVP-001 with imaging. The ultimate goal of this research program is development of a gadolinium-free alternative to current general purpose MRI contrast agents.
Conditions
- Central Nervous System (CNS) Lesions
- Brain Metastases
- Brain Neoplasms
- Brain Neoplasms, Benign
- Brain Tumor, Primary
- Brain Tumor, Recurrent
- Brain Tumors
- Brain Cancer
- Brain Tumor
- Brain Neoplasm, Primary
- Multiple Sclerosis
- Multiple Sclerosis Brain Lesion
- Neurofibroma
- Acoustic Neuroma
- CNS Tumor
- CNS Lesion
- CNS Metastases
- CNS Cancer
- CNS Lymphoma
- Von Hippel Lindau
- Meningioma
- Glioma
- Schwannomas
- Neuroinflammation
- Neoplasia
Interventions
RVP-001Drug
MRI contrast agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: From time of dosing to 7 days post dose
- Lesion visualization criteria for RVP-001 enhanced MRI compared to unenhanced MRITime frame: 1 day
- Lesion visualization criteria for RVP-001 compared to gadolinium-based contrast agent (GBCA)Time frame: 1 day
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Yale New Haven Hospital
New Haven, Connecticut
Massachusetts General Hospital
Boston, Massachusetts
Brigham & Women's Hospital
Boston, Massachusetts
University of Missouri
Columbia, Missouri
Duke University Medical Center
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.